Abstract
Purpose of Investigation: Dienogest is marketed in Japan as the first time in the world for novel treatment of endometriosis. This paper details the retrospective investigation how effective long-term use of dienogest is for the treatment of endometriosis. Materials and Methods: Data on 21 patients of diagnosed as endometriosis/adenomyosis and treated with dienogest for more than 12 months (ten patients with 60-month period) were collected. Results: Dienogest was effective in reducing pain and size of ovarian endometrioma, while the size of adenomyosis remained the same size as before treatment. The most frequent adverse effects were irregular bleeding. There was no reduction in bone mineral density after 60 months while plasma estradiol was maintained at a slightly lower level. Clinical parameters for did not change during a 60-month period. Conclusions: These results show that dienogest is safe to use for at least five years and is an effective treatment for endometriosis for long periods.
Highlights
Endometriosis is a common, chronic, and benign disease found in approximately 10% of women of reproductive age [1]
GnRH agonists have been proven to be effective for both pain and endometriosis lesions, but use of these agents is restricted to a period of six months because a hypoestrogenic state leads to a reduction in bone mineral density [12]
The data of 21 patients diagnosed with endometriosis or adenomyosis was collected
Summary
Endometriosis is a common, chronic, and benign disease found in approximately 10% of women of reproductive age [1]. Several types of hormonal agents are currently used: combined oral contraceptives (COCs) have a relatively safer profile and are suitable for long-term use [7]. They are effective in reducing dysmenorrhea related to endometriosis [8]. GnRH agonists have been proven to be effective for both pain and endometriosis lesions, but use of these agents is restricted to a period of six months because a hypoestrogenic state leads to a reduction in bone mineral density [12]. Danazol is effective but use of this drug is restricted to a period of four months because of androgenic side effects and an increase in the risk of thrombosis [13] For these reasons, drugs which have comparable effectiveness to GnRH agonists but with safer profiles are awaited [14]. The authors investigated long-term dienogest therapy to elucidate its efficacy and safety, by collecting and retrospectively analyzing data on patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical and Experimental Obstetrics & Gynecology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
